Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32305099

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 May
First author
Pfisterer J

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 May;21(5):614-615. doi: 10.1016/S1470-2045(20)30178-9.
    note
    Source null
    related pmid
    32305100
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Jun;23(6):e248. doi: 10.1016/S1470-2045(22)00303-5.
    note
    Source null
    related pmid
    35654064
    relationship
    Erratum in

Authors and identifiers

  1. name
    Pfisterer J
    type
    Author
  2. name
    Shannon CM
    type
    Author
  3. name
    Baumann K
    type
    Author
  4. name
    Rau J
    type
    Author
  5. name
    Harter P
    type
    Author
  6. name
    Joly F
    type
    Author
  7. name
    Sehouli J
    type
    Author
  8. name
    Canzler U
    type
    Author
  9. name
    Schmalfeldt B
    type
    Author
  10. name
    Dean AP
    type
    Author
  11. name
    Hein A
    type
    Author
  12. name
    Zeimet AG
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Pfisterer J
    type
    Author
  2. name
    Shannon CM
    type
    Author
  3. name
    Baumann K
    type
    Author
  4. name
    Rau J
    type
    Author
  5. name
    Harter P
    type
    Author
  6. name
    Joly F
    type
    Author
  7. name
    Sehouli J
    type
    Author
  8. name
    Canzler U
    type
    Author
  9. name
    Schmalfeldt B
    type
    Author
  10. name
    Dean AP
    type
    Author
  11. name
    Hein A
    type
    Author
  12. name
    Zeimet AG
    type
    Author
bibliography ids
  1. nci-bib-b7645e52c94a7eef9b009e72
book metadata
content sha256
80e93aea11b73167cd0d3be04b13d589df5e6358c5a171120903c226ffcbc6f0
document type
citation
dois
  1. 10.1016/S1470-2045(20)30142-X
electronic publication date
display
2020 Apr 16
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32305099
immutable id
pubmed:32305099@80e93aea11b73167cd0d3be04b13d589df5e6358c5a171120903c226ffcbc6f0
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
699-709
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 May;21(5):614-615. doi: 10.1016/S1470-2045(20)30178-9.
    note
    Source null
    related pmid
    32305100
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Jun;23(6):e248. doi: 10.1016/S1470-2045(22)00303-5.
    note
    Source null
    related pmid
    35654064
    relationship
    Erratum in
outcomes validated
false
pmid
32305099
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
88fb88198f61cd09a0a807d4869676f6f579addd4785e6f5f8812cc71c0bb163
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 May
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32305099/
title
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice